dpp-4 and glp-1 receptor agonists inhibitors Pathway, Pharmacodynamics The action of DPP4 degrades

Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome

By acting on MC3R and MC4R in the central nervous system, it can modulate appetite, energy homeostasis, and sexual function

China: Demand for GLP-1 companion products in China is projected to grow at around an 11.7% CAGR through 2036, supported by rapid expansion of domestic GLP-1 user base for weight management, and formulation technologies, and growing focus on high-quality and science-backed companion products for muscle preservation and GI side-effect management

Cleara Biotech FOXO4-DRI development status

Vallee A, Lecarpentier Y, Guillevin R, Vallee JN